Optivate in People With Von Willebrand Disease Undergoing Surgery

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01651468` - The Effect of the Nutraceutical "Hemofix" on the Coagulation System	N/A
Active, not recruiting	`NCT00555555` - Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients	Phase 4
Terminated	`NCT00178542` - Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle	N/A
Completed	`NCT02552576` - Study of Voncento® in Subjects With Von Willebrand Disease	Phase 4
Recruiting	`NCT02869074` - Molecular and Clinical Profile of Von Willebrand Disease in Spain
Completed	`NCT01602419` - Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
Completed	`NCT01224808` - Extension Study of Biostate in Subjects With Von Willebrand Disease	Phase 3
Withdrawn	`NCT00694785` - A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B	Phase 2
Completed	`NCT00805051` - Acquired Von Willebrand Syndrome in Severe Aortic Stenosis	N/A
Completed	`NCT02246881` - A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.	Phase 3
Completed	`NCT00168090` - Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)	Phase 4
Completed	`NCT04657887` - Registry of Patients With Von WilLEbrand Disease Treated With Voncento®
Withdrawn	`NCT00630448` - Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)	N/A
Terminated	`NCT00387192` - A Study With OPTIVATE® in People With Von Willebrand Disease	Phase 3
Completed	`NCT02973087` - rVWF IN PROPHYLAXIS	Phase 3
Completed	`NCT01410227` - Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)	Phase 3
Completed	`NCT01949220` - Willebrand International Non-interventional Global Surveillance
Completed	`NCT01589848` - Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador	N/A
Completed	`NCT00941616` - Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease	Phase 2/Phase 3
Completed	`NCT00557908` - The Von Willebrand Disease (VWD) International Prophylaxis Study	N/A

NCT number	NCT00404300
Study type	Interventional
Source	Bio Products Laboratory
Contact
Status	Terminated
Phase	Phase 3
Start date	February 2007
Completion date	September 2008

Optivate in People With Von Willebrand Disease Undergoing Surgery

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms